Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis

Nurlan Tabriz, Kuliya Skak, Lazzat T. Kassayeva, Bauyrzhan K. Omarkulov, Marina A. Grigolashvili

2020

Closed access Metadata (CSL-JSON)
DOI 10.1089/mdr.2019.0326
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Half a million new cases of multidrug-resistant tuberculosis (MDR-TB) are registered annually, and therefore, the issue of the development of new fast and reliable methods for diagnosis of tuberculosis (TB) remains urgent in modern phthisiology. Aims: The aim of this study was to investigate the effects of the Xpert MTB/RIF molecular genetic method on the diagnosis, clinical and radiological features, and efficacy of treatment of MDR-TB. Materials and Methods: Patients with MDR-TB were divided into two groups. The first (study) group included patients ( n = 412) in whom a mutation in the gene responsible for the presence of Mycobacterium tuberculosis ( MTB ) and resistance to rifampicin were detected using the Xpert MTB/RIF assay. The second group consisted of patients ( n = 540) in whom TB was diagnosed using bacterioscopy and multidrug resistance was detected using inoculation on dense and liquid culture media. The results of bacterioscopic, bacteriological, molecular genetic, clinical studies and the efficacy of the treatment of 952 patients with MDR pulmonary TB were studied. The result of GeneXpert MTB/RIF was compared with the results of sputum bacterioscopy and culture methods on a dense Levenshtein–Jensen nutrient medium and on a liquid nutrient medium in a BACTEC 960 automated microbiological system. Results: The “Successful treatment” outcome (“cured” and “treatment completed”) prevailed among patients who underwent timely diagnosis of MDR-TB using the Xpert MTB/RIF assay and reached 73.8%. In the second group of patients, it was 49.3% ( p = 0.000). Conclusion: Timely diagnosis of MDR-TB using the Xpert MTB/RIF assay increased the efficacy of anti-TB chemotherapy.